Adding 10 years to healthy human lifespan
Backed by Sam Altman with $180M, Retro Biosciences is pursuing three approaches to extend healthy human lifespan: partial reprogramming, autophagy, and plasma-inspired therapeutics.
| Drug / Program | Indication | Phase | Technology |
|---|---|---|---|
| Reprogramming program | Aging | Preclinical | Partial Reprogramming |
| Autophagy program | Aging | Preclinical | Small molecule |
Life Biosciences launched the first-ever human trial of epigenetic reprogramming in January 2026 — an AAV gene therapy that uses three Yamanaka factors to reverse aging in the eye. Here's the full story of the company, its science, and what it means for the future of longevity medicine.
From billion-dollar reprogramming ventures to canine longevity drugs, here are the biotech companies leading the charge against aging in 2026.